Contact

Our portfolio

AlpENa Biosciences

Innovating cancer therapeutics, AlpENa Biosciences develops bispecific antibodies that activate immune cells to target and destroy tumor cells. Their research, based on the work of Professor Marjolein van Egmond, shows promising potential in a variety of oncology treatments. The company is backed by Versant Ventures in order to advance these therapies.

  • Institute: Amsterdam UMC
Industry: Oncology, Therapeutics
  • Founding year: 2023
Visit website

Want to get in contact about AlpENa Biosciences?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
uniQure
Pioneering gene therapy, uniQure develops transformative treatments using its AAV-based technology platform.
Rsouth Antibodies
Developing therapeutic antibodies, including the blockbuster RSV drug Nirsevimab.
InSteps
Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.
DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies.
Explore full AAV portfolio
Contact